首页> 美国卫生研究院文献>Haematologica >Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers

【2h】

Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers

机译：来那度胺和地塞米松挽救治疗复发/难治性套细胞淋巴瘤的临床结果及其对微环境和新血管生成生物标志物的影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundPreclinical studies have highlighted the activity of lenalidomide in mantle cell lymphoma and its anti-proliferative synergy with dexamethasone.

机译：背景临床前研究强调来那度胺在套细胞淋巴瘤中的活性及其与地塞米松的抗增殖协同作用。

著录项

期刊名称 Haematologica
作者
Francesco Zaja; Stefano De Luca; Umberto Vitolo; Lorella Orsucci; Alessandro Levis; Flavia Salvi; Chiara Rusconi; Erika Ravelli; Alessandra Tucci; Chiara Bottelli; Monica Balzarotti; Ercole Brusamolino; Maurizio Bonfichi; Stefano A. Pileri; Elena Sabattini; Stefano Volpetti; Chiara Monagheddu; Angelo Vacca; Roberto Ria; Renato Fanin;
展开▼
作者单位

展开▼
年(卷),期 2012(97),3
年度 2012
页码 416–422
总页数 7
原文格式 PDF
正文语种
中图分类血液学检验;
关键词
lenalidomide dexamethasone mantle cell lymphoma relapsed/refractory disease salvage treatment;

机译：来那度胺;地塞米松;套细胞淋巴瘤;复发/难治性疾病;挽救治疗;

相似文献

外文文献
中文文献
专利

1. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers | Haematologica [J] . Francesco Zaja, Stefano De Luca, Umberto Vitolo, Haematologica . 2012,第3期

机译：来那度胺和地塞米松治疗复发/难治性套细胞淋巴瘤的临床疗效及对微环境和新血管生成生物标志物的影响血液学
2. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: A phase 1/2 clinical trial [J] . WangM., FayadL., Wagner-BartakN., The lancet oncology . 2012,第7期

机译：来那度胺联合利妥昔单抗治疗复发或难治性套细胞淋巴瘤的患者：1/2期临床试验
3. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): Report of a phase I/II trial [J] . HopfingerG., N?sslingerT., LangA., Annals of hematology . 2014,第3期

机译：来那度胺联合伏立诺他和地塞米松治疗复发/难治性外周T细胞淋巴瘤（PTCL）：I / II期试验报告
4. CLINICAL EVALUATION OF A CD40-ACTIVATED B CELL VACCINE TO PREVENT LYMPHOMA RELAPSE INDOGS [C] . Nicola J. Mason Conference of the American College of Veterinary Internal Medicine . 2014

机译：CD40活化B细胞疫苗的临床评价，以防止犬淋巴瘤复发
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Combination of Decitabine and a Modified Regimen of Cisplatin Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure [O] . Junxia Hu, Xin Wang, Fei Chen, 2021

机译：联合丁滨红细胞糖苷和地塞米松的改良方案：第二线治疗失败后复发或难治性弥漫性大B细胞淋巴瘤的潜在救助方案
7. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers [O] . Zaja, Francesco, De Luca, Stefano, Vitolo, Umberto, 2011

机译：来那度胺和地塞米松挽救治疗复发/难治性套细胞淋巴瘤的临床结果及其对微环境和新血管生成生物标志物的影响
8. Innate Anti-Breast Cancer Activity of -T cells: A Novel Biological and Clinical Approach to the Treatment of Relapsed or Refractory Breast Cancer [R] . Lopez, R. D. 2009

机译：T细胞的先天性抗乳腺癌活性：一种治疗复发或难治性乳腺癌的新型生物和临床方法

Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers

摘要

著录项

相似文献

相关主题

期刊订阅